Umecrine Cognition receives Notice of Allowance in the US for patents protecting second-generation GAMSA compounds
Umecrine Cognition receives Notice of Allowance in the US for patents protecting second-generation GAMSA compounds
STOCKHOLM – September 7, 2026. Umecrine Cognition today announced that it has received two Notices of Allowance from the United States Patent and Trademark Office (USPTO) for the company’s patent applications directed to two second-generation substances in the same drug class (GAMSA) as its current clinical drug candidate golexanolone. The new generation of compounds will fit into the company’s development area targeting neurodegenerative diseases.
Umecrine Cognition has received Notice of Allowances from the US Patent and Trademark Office for patents protecting the compounds GR3053 and GR3055, the company’s second-generation of GAMSA (GABA-A receptor Modulating Steroid Antagonist) compounds. The patents will provide NCE (New Chemical Entity) patent protection in the US until at least 2042.
With these two patents GR3053 and GR3055 extend Umecrine Cognition's novel drug-class platform, for neurodegenerative diseases, where the company sees early commercial opportunities.
"With our second-generation compounds, we continue targeting the neurobiology in neurodegenerative diseases. Data from current studies of our existing drug candidates, in part supported by the Michael J Fox Foundation, show positive, normalizing effects in models exhibiting Parkinson disease-like attributes. In the short term, we see commercial opportunities in non-motor symptom management, with the future intention to evaluate potential effects also in movement dysfunction," comments Dr. Viktor Drvota, CEO of Umecrine Cognition.
For further information, please contact:
Viktor Drvota, CEO, Umecrine Cognition AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@umecrine.se
About Umecrine Cognition
Umecrine Cognition AB is developing a completely new class of drugs for the treatment of symptoms in the central nervous system related to chronic neuroinflammation – a devastating brain distortion that can lead to severely impaired cognition and fatigue. Chronic neuroinflammation can occur as a result of a number of underlying conditions, including a range of liver diseases as well as neurodegenerative diseases, such as Parkinson’s disease. Results from an internationally acclaimed Phase 2 clinical study indicate that the company's most advanced drug candidate, the GABAA receptor-modulating steroid antagonist golexanolone, normalizes brain signaling and improves cognition and alertness in patients with hepatic encephalopathy. A Phase 2 study is currently ongoing in patients with primary biliary cholangitis. Further, based on intriguing preclinical data, the company is considering pursuing the development of golexanolone in patients with Parkinson’s disease. For more information, visit www.umecrinecognition.com.